Drug Information

Drug General Information
Drug ID
D0XF5P
Former ID
DNC009136
Drug Name
(R)-3-(naphthalen-2-ylmethoxy)pyrrolidine
Drug Type
Small molecular drug
Indication Discovery agent Investigative [530012]
Formula
C15H17NO
Canonical SMILES
C1CNCC1OCC2=CC3=CC=CC=C3C=C2
InChI
1S/C15H17NO/c1-2-4-14-9-12(5-6-13(14)3-1)11-17-15-7-8-16-10-15/h1-6,9,15-16H,7-8,10-11H2/t15-/m1/s1
InChIKey
IQZVBBALTJFFCB-OAHLLOKOSA-N
PubChem Compound ID
44592119
Target and Pathway
Target(s) Sodium-dependent noradrenaline transporter Target Info Inhibitor [530012]
Sodium-dependent serotonin transporter Target Info Inhibitor [530012]
Sodium-dependent dopamine transporter Target Info Inhibitor [530012]
Potassium voltage-gated channel subfamily H member 2 Target Info Inhibitor [530012]
KEGG Pathway Serotonergic synapsehsa04728:Dopaminergic synapse
Parkinson's disease
Cocaine addiction
Amphetamine addiction
Alcoholism
NetPath Pathway TCR Signaling Pathway
PANTHER Pathway Adrenaline and noradrenaline biosynthesisP04373:5HT1 type receptor mediated signaling pathway
5HT2 type receptor mediated signaling pathway
5HT3 type receptor mediated signaling pathway
5HT4 type receptor mediated signaling pathwayP00001:Adrenaline and noradrenaline biosynthesis
Parkinson disease
Dopamine receptor mediated signaling pathway
Pathway Interaction Database Alpha-synuclein signaling
PathWhiz Pathway Muscle/Heart Contraction
Reactome Na+/Cl- dependent neurotransmitter transportersR-HSA-442660:Na+/Cl- dependent neurotransmitter transportersR-HSA-1296072:Voltage gated Potassium channels
WikiPathways Monoamine Transport
NRF2 pathway
Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compoundsWP727:Monoamine Transport
SIDS Susceptibility Pathways
Synaptic Vesicle Pathway
Serotonin Transporter ActivityWP727:Monoamine Transport
Dopaminergic Neurogenesis
Parkinsons Disease Pathway
Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds
Neurotransmitter Clearance In The Synaptic CleftWP706:SIDS Susceptibility Pathways
Hematopoietic Stem Cell Differentiation
Potassium Channels
References
Ref 530012Bioorg Med Chem Lett. 2009 Apr 15;19(8):2329-32. Epub 2009 Feb 20.Design and optimization of selective serotonin re-uptake inhibitors with high synthetic accessibility. Part 1.
Ref 530012Bioorg Med Chem Lett. 2009 Apr 15;19(8):2329-32. Epub 2009 Feb 20.Design and optimization of selective serotonin re-uptake inhibitors with high synthetic accessibility. Part 1.

If you find any error in data or bug in web service, please kindly report it to Dr. Tang and Dr. Mou.